← Back to Search

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

N/A
Waitlist Available
Led By David Keren, MD
Research Sponsored by InheRET, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up follow up surveys 12- to 18-months following completion of the inheret program.
Awards & highlights
No Placebo-Only Group

Summary

This study will evaluate the impact InheRET™, an online family history gathering and risk assessment reporting tool, has on facilitating National Comprehensive Cancer Network(NCCN) guideline compliant referrals for cancer genetic counseling/genetic evaluation by decreasing and/or removing the barriers of 1) time-consuming in-clinic 3-generation family history collection, and 2) interpretation of the family and personal history in light of current NCCN guidelines. Identifying individuals at increased risk for cancer has been shown to decrease morbidity and mortality in multiple clinical settings. Investigators hypothesize that InheRET will prove to be accurate, efficient, and accessible, and that its use will improve identification of individuals at risk for inherited susceptibility to cancer. The investigators propose also that using this tool will result in a reduction of inappropriate genetic counseling referrals and reduce unnecessary genetic testing in both primary and specialty care settings. InheRET will allow health care providers to focus resources on individuals at higher risk for developing cancer.

Eligible Conditions
  • Cancer Syndromes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow up surveys 12- to 18-months following completion of the inheret program.
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow up surveys 12- to 18-months following completion of the inheret program. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pre- and Post-Rate of Referrals of Patients to Genetic Counseling from Primary Care Clinics
Secondary study objectives
Patient Acceptance of InheRET
Physician Acceptance and Impact
Qualitative Impact on Patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Post-InheRETExperimental Treatment3 Interventions
Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
Group II: Pre-InheRETActive Control1 Intervention
Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.

Find a Location

Who is running the clinical trial?

University of MichiganOTHER
1,860 Previous Clinical Trials
6,435,688 Total Patients Enrolled
InheRET, IncLead Sponsor
David Keren, MDPrincipal InvestigatorInheRET, Inc
~425 spots leftby Dec 2025